Decro Pharma Private Limited - Due diligence report

A 360° intelligence report on Decro Pharma Private Limited: trust score, financial health, credit view, compliance, directors, growth and di…

2020-10-21 Indrad, Gujarat Active Unlisted Active Compliant
Share
Connect MCP
DP Decro Pharma Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Decro Pharma Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
89/100
Trust Score
Low Risk

Decro Pharma Private Limited is assessed as Low Risk with a Trust Score of 89/100. Decro Pharma Private Limited is an active private limited indian non-government company incorporated in 2020, operating in the Chemicals and Materials sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.

Report generated on 10 Aug 2026 from the latest processed filings. Decro Pharma Private Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
89/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
100/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
80/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
35/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
95/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
80/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 3 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 35/100 Caution Indicated
  • Negative operating earnings - debt service depends on external support.
  • Open charges exceed net worth - secured lenders rank ahead.
  • Elevated gearing (D/E 38%).
  • Working-capital cover adequate.
  • Profitable - internal accruals available.

Charges position: 2 open (38.80 cr) · 0 satisfied (-).

Banking relationships (from registered charges)
LenderChargesAmount
State Bank Of India2 48.0 cr
Compliance Score: 100/100 Low Risk
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
SANGITABEN RAKESHKUMAR PATEL 01234567 Director 01/04/2018 6 yrs Approved
RAKESH AMBALAL PATEL 01234567 Director 01/04/2018 6 yrs Approved
ARVINDBHAI PATEL 01234567 Director 01/04/2018 6 yrs Approved
BHIKAN NIMBA PATIL 01234567 Director 01/04/2018 6 yrs Approved
NARENDRA RAJDEV PANDEY 01234567 Director 01/04/2018 6 yrs Approved
HARESHBHAI KALABHAI PATEL 01234567 Director 01/04/2018 6 yrs Approved
  • 6 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
3 allotment(s) · 1 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 95 · Distress 80
Growth signals & trust indicators
Revenue acceleration: +1.42 over 2 year(s).
Latest year revenue grew 2.1x.
Profit expanded 24% year-on-year.
Asset base grew 0.86 - capacity expansion.
Net margin improved to 61%.
Operating for 5 years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Outside liabilities up 38% in a year.
2 open charge(s) registered - assets are encumbered.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence91/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 1 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment65/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 2 open charge(s) of 38.80 cr already registered.
  • Compliance record supports lending.
Investor view88/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 5 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
30 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
16 Jan 2023
Securities allotted
500000 Equity Shares - 50.00 Lakh raised
10 Sep 2022
Securities allotted
2000000 Equity Shares - 2.00 cr raised
31 May 2022
Securities allotted
2990000 Equity Shares - 2.99 cr raised
31 Mar 2022
Share transfer (FY 2022)
500.00000000 shares to SANGITABEN RAKESHKUMAR PATEL
30 Mar 2022
Charge created
State Bank Of India - 19.40 cr
30 Nov 2021
Director ceased
SANGITABEN RAKESHKUMAR PATEL
Director ceased
ARVINDBHAI PATEL
08 May 2021
Director appointed
SANGITABEN RAKESHKUMAR PATEL (Director)
Director appointed
ARVINDBHAI PATEL (Director)
21 Oct 2020
Incorporated
Registered with Roc Ahmedabad
Director appointed
RAKESH AMBALAL PATEL (Director)
Director appointed
BHIKAN NIMBA PATIL (Director)
Director appointed
NARENDRA RAJDEV PANDEY (Director)
10

Key Observations

Auto-generated from the data above
Revenue grew 1.42 over the last 2 financial year(s).
Net profit margin moved from 2.1x to 24%.
Debt-to-equity stands at 0.86 - leverage worth monitoring.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
6 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Capital has been raised through 3 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Med4Health Laboratories Private Limited U33309MP2016PTC041977 Bhopal, Madhya Pradesh, India
Aarpik Remedies Private Limited U24110GJ1997PTC032952 Ahmedabad, Gujarat, India
Medicean Pharmaceuticals Private Limited U24299UP2021PTC154918 Lucknow, Uttar Pradesh, India
M.Dhanasekara Pandian & Sons Private Limited U24294TN1984PTC010854 Madurai, Tamil Nadu, India
Gavyadhara Herbal Private Limited U33112PN2018PTC179515 Sangli, Maharashtra, India
Flowchem Pvt Ltd U24110TG1982PTC003641 Hyderabad, Telangana, India
Altius Biochem Private Limited U24231GJ2021PTC122626 Ahmedabad, Gujarat, India
Godha Chemicals Pvt Ltd U24231RJ1990PTC005666 Udaipur, Rajasthan, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Decro Pharma Private Limited before audits and certifications: compliance score 100/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Decro Pharma Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 35/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 95/100, margin trends, ownership structure and peer set for Decro Pharma Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 89/100, distress signals and MSME payment-delay disclosures - know whether Decro Pharma Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Decro Pharma Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Decro Pharma Private Limited an active company?

Decro Pharma Private Limited has MCA status “Active” with a compliance score of 100/100 (Low Risk).

Is Decro Pharma Private Limited financially healthy?

Decro Pharma Private Limited has a Financial Health Score of 80/100 (Low Risk) based on its filed financial statements.

Should I do business with Decro Pharma Private Limited?

Its overall Trust Score is 89/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Decro Pharma Private Limited?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 6 active director(s) are on record.

Does Decro Pharma Private Limited have loans or charges against its assets?

2 open charge(s) are registered against its assets.

Is Decro Pharma Private Limited up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 100/100 (Low Risk).

Is it risky to lend to Decro Pharma Private Limited?

Its Credit Risk Score is 35/100 (Caution Indicated). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.